Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 16/20 | 0.92 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.92 |
| ▸ | MEN1 | O00255 | 1/20 | 0.92 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.92 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.92 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.92 |
| ▸ | CCR2 | P41597 | 1/20 | 0.92 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.92 |
| ▸ | BLM | P54132 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.92 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5611617 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL29490414 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL19038 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL414153 | 0.94 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7612104 | 0.94 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7610931 | 0.94 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL6889125 | 0.94 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL1259387 | 0.94 | CXCR4 (0.81) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL1649655 | 0.93 | CXCR4 (0.93) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL123040 | 0.93 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369428-A1 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY- ACADEMIC COOPERATION FOUNDATION (KR) | 2018-12-27 | — | — | US | claimed |
| EP-3281643-A2 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | Kyungpook National University Industry-Academic Cooperation Foundation (KR) | 2018-02-14 | — | — | EP | claimed |
| US-20200138982-A1 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY- ACADEMIC COOPERATION FOUNDATION (KR) | 2020-05-07 | — | — | US | disclosed |
| US-10583206-B2 | Radioactive probe for detecting hydrogen sulfide | Kyungpook National University Industry-Academic, Cooperation Foundation (KR) | 2020-03-10 | — | — | US | disclosed |
| US-20180369428-A1 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY- ACADEMIC COOPERATION FOUNDATION (KR) | 2018-12-27 | — | — | US | disclosed |
| EP-3281643-A2 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | Kyungpook National University Industry-Academic Cooperation Foundation (KR) | 2018-02-14 | — | — | EP | disclosed |
| US-9233971-B2 | Lipomacrocycles and uses thereof | AGAVE PHARMA, INCORPORATED | 2016-01-12 | — | — | US | disclosed |
| US-9233971-B2 | Lipomacrocycles and uses thereof | AGAVE PHARMA, INCORPORATED | 2016-01-12 | — | — | US | disclosed |
| US-20130156851-A1 | LIPOMACROCYCLES AND USES THEREOF | AGAVE PHARMA, INCORPORATED | 2013-06-20 | — | — | US | disclosed |
| US-20130156851-A1 | LIPOMACROCYCLES AND USES THEREOF | AGAVE PHARMA, INCORPORATED | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369428-A1 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | TST, CTH, CBS | CXCR4 3011/4885HRH3 172/4885MEN1 2258/4885 |
| US-20130156851-A1 | LIPOMACROCYCLES AND USES THEREOF | LIPC, LIPA, LIPE | CXCR4 373/4885HRH3 321/4885MEN1 1689/4885 |
| US-20200138982-A1 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | TST, SCLY, CTH | CXCR4 3652/4885HRH3 214/4885MEN1 2360/4885 |
| US-10583206-B2 | Radioactive probe for detecting hydrogen sulfide | TST, SCLY, CTH | CXCR4 3652/4885HRH3 214/4885MEN1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.